131 related articles for article (PubMed ID: 38491962)
1. Quantifying preferences for urea cycle disorder treatments using a discrete choice experiment.
Edelblut J; Skaar JR; Hilton J; Seibt M; Martin K; Hadker N; Quartel A; Steiner RD
J Med Econ; 2024; 27(1):506-517. PubMed ID: 38491962
[TBL] [Abstract][Full Text] [Related]
2. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.
Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A
Patient; 2012; 5(1):33-44. PubMed ID: 22077619
[TBL] [Abstract][Full Text] [Related]
4. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
5. Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment.
Morse AM; Krahn L; Flygare J; Kushida C; Thorpy MJ; Athavale A; Gudeman J
Adv Ther; 2023 Jul; 40(7):3199-3216. PubMed ID: 37243863
[TBL] [Abstract][Full Text] [Related]
6. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
Fifer S; Rose J; Hamrosi KK; Swain D
BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
[TBL] [Abstract][Full Text] [Related]
7. Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences.
Veldwijk J; Smith IP; Oliveri S; Petrocchi S; Smith MY; Lanzoni L; Janssens R; Huys I; de Wit GA; Groothuis-Oudshoorn CGM
Med Decis Making; 2024 Feb; 44(2):203-216. PubMed ID: 38178591
[TBL] [Abstract][Full Text] [Related]
8. Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.
Panchal R; Nguyen D; Ghule P; Li N; Giannouchos T; Pan RJ; Biskupiak J; Britton L; Nohavec R; Slager S; Ngorsuraches S; Brixner D
J Manag Care Spec Pharm; 2023 Feb; 29(2):139-150. PubMed ID: 36705280
[No Abstract] [Full Text] [Related]
9. Older adult patient preferences for the content and format of prescription medication labels - A best-worst scaling and discrete choice experiment study.
Malhotra R; Suppiah SD; Tan YW; Sung P; Tay SSC; Tan NC; Koh GC; Chan A; Chew LST; Ozdemir S;
Res Social Adm Pharm; 2023 Nov; 19(11):1455-1464. PubMed ID: 37507340
[TBL] [Abstract][Full Text] [Related]
10. Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
Schwedt TJ; Martin A; Kymes S; Talon B; Lee XY; Cady R; Asher D; Karnik-Henry M; Mulvihill E; Bates D; Beusterien K
Headache; 2023 Apr; 63(4):484-493. PubMed ID: 36753057
[TBL] [Abstract][Full Text] [Related]
11. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
12. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
13. Attribute Selection for a Discrete Choice Experiment Incorporating a Best-Worst Scaling Survey.
Webb EJD; Meads D; Lynch Y; Judge S; Randall N; Goldbart J; Meredith S; Moulam L; Hess S; Murray J
Value Health; 2021 Apr; 24(4):575-584. PubMed ID: 33840436
[TBL] [Abstract][Full Text] [Related]
14. Patient and parent preferences for immunoglobulin treatments: a conjoint analysis.
Mohamed AF; Kilambi V; Luo MP; Iyer RG; Li-McLeod JM
J Med Econ; 2012; 15(6):1183-91. PubMed ID: 22846048
[TBL] [Abstract][Full Text] [Related]
15. Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders.
Cederbaum SD; Edwards J; Kellmeyer T; Peters Y; Steiner RD
Mol Genet Metab; 2023 Apr; 138(4):107558. PubMed ID: 37004302
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis.
Hincapie AL; Penm J; Burns CF
J Manag Care Spec Pharm; 2017 Aug; 23(8):822-830. PubMed ID: 28737987
[TBL] [Abstract][Full Text] [Related]
17. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
Mühlbacher A; Bethge S
Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
[TBL] [Abstract][Full Text] [Related]
18. Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment.
van den Wijngaard L; Rodijk IC; van der Veen F; Gooskens-van Erven MH; Koks CA; Verhoeve HR; Mol BW; van Wely M; Mochtar MH
Hum Reprod; 2015 Feb; 30(2):331-7. PubMed ID: 25432926
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
[TBL] [Abstract][Full Text] [Related]
20. Patient versus physician preferences for lipid-lowering drug therapy: A discrete choice experiment.
Zhang L; Chen J; Cao Z; Zhang M; Ma R; Zhang P; Yao G; Li X
Health Expect; 2024 Apr; 27(2):e14043. PubMed ID: 38590082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
